ARDS - Albireo's Positive Data And Other News: The Good Bad And Ugly Of Biopharma
Albireo reports positive data from Phase 3 trial
Albireo Pharma, Inc. (ALBO) reported positive top-line data from PEDFIC 1 trial for odevixibat. The study met both its primary endpoints. The drug candidate is a highly potent, non-systemic ileal bile acid transport inhibitor. It is being developed for treating progressive familial intrahepatic cholestasis. The company stated that its regulatory submissions for approval are on track.
The primary analysis demonstrated that the data met the primary endpoint pertaining the proportion of positive pruritus assessments. 53.5 percent of the participants in the drug candidate arm met the requirement